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Abstract 
We presented 9 recurrent head and neck carcinoma patients. Priorly all of them had 
received radiochemotherapy. We used cetuximab and irradiation concomitantly. Overall 
survival analysis of the patients was performed using the Kaplan-Meier method on SPSS 
version 15.0. Based on this calculation, mean follow-up duration is 12.8 months. Mean 
survival time is 19.8 months and annual mean survival rate is 59.3%. 
Introduction 
Head and neck cancers constitute almost 6% of all cancers worldwide. In Europe, 
150,000 cases of newly diagnosed head and neck cancer are reported each year. It is well 
known that prognosis of patients with inoperable local recurrent squamous cell head and 
neck cancer (SCHNC) is considerably poor. There are limited treatment options available 
for these patients, including second-line radiotherapy (RT), chemotherapy (CT), 
chemoradiotherapy (CRT) or supportive care alone [1]. While the average survival time 
of untreated patients is only 4 months, response rates increase by 30–40% and survival 
reaches 6–9 months in patients administered platinum-based combination therapy. Mean 
survival does not exceed 100 days in patients with progressing disease while undergoing 
CT [2]. Epidermal growth factor receptor (EGFR) is a member of the human epidermal 
receptor (HER) family. Abnormal levels of EGFR expression can be seen in 80–100% of  










head and neck tumors. There is a positive correlation between the level of EGFR 
expression and bad prognosis, metastatic disease and short survival times. Cetuximab 
(CTX) is an IgG1 monoclonal antibody which inhibits binding of ligands to EGFR [3]. 
Recent studies have shown that concomitant administration of CTX with RT results in 
significantly better local-regional control compared to RT alone in patients with locally 
advanced SCHNC [4, 5]. Synergy of CTX with antitumor effects of cisplatin has been 
demonstrated in xenograft models [6]. Accordingly, increased response and survival rates 
were reported in studies using CTX concomitant with cisplatin/carboplatin in patients 
with platinum-based CT-resistant local recurrent SCHNC [7–9]. There are no studies in 
the literature demonstrating that the efficacy of CTX concomitant with RT in locally 
advanced disease also applies to locally advanced recurrent disease. Based on this, we 
evaluated the data on CTX administration concomitant with second-line RT in patients 
with locally advanced recurrent SCHNC (except nasopharynx) whose disease progressed 
despite CT or who could not be administered platinum-based CT. None of the patients 
had distant metastasis. 
Patients and Methods 
Patient Characteristics 
Nine patients [mean age 55 (42–65) years, 7 males and 2 females] with locally advanced recurrent 
SCHNC were admitted to our clinics between May 2008 and May 2010. On admission, all patients had a 
Karnofsky performance score between 80 and 90. Two patients had carcinoma of the larynx with 
recurrence in tracheostomy, 2 had carcinoma of the larynx with neck metastasis, 2 had carcinoma of the 
lip with neck metastasis, 2 had carcinoma of the mouth base with recurrence and 1 patient had 
carcinoma of the tongue base with neck metastasis. According to the regions of primary disease, all 
patients had previously received curative doses of RT concomitant with cisplatin in our clinics. 
Following primary treatment, based on the local recurrence observed in these patients, 2 underwent 
salvage surgery, while the others received various combinations of systemic treatments including 
cisplatin, methotrexate and taxanes for different durations. One patient was on imatinib treatment, due 
to leukemia, and could not tolerate CT. CTX concomitant with second-line RT was administered to 
patients who did not show distant metastasis on positron emission tomography/computed tomography 
scans. 
Radiotherapy 
Tomography scans with 5-mm slice intervals were performed for treatment planning. 3-D conformal 
RT was planned based on the tomography scans and considering the tolerance doses of critical organs 
such as the spinal cord and mandibula. Computed tomography, positron emission tomography/ 
computed tomography scans or MRI was used to determine target volume. Treatment was administered 
by a linear accelerator device using the energies of photons and electrons. RT doses were between 20 
and 70 Gy; 4 of 5 patients with neck metastases received 20 Gy, 1 received 30 Gy, 1 of 2 patients with 
carcinoma of the mouth base received 40 Gy, 1 received 20 Gy and 2 patients with recurrence in 
tracheostomy received 70 Gy of RT.  
CTX Administration 
CTX was administered to all patients as a 400 mg/m
2 loading dose before RT and a 250 mg/m
2 
weekly maintenance dose. Four patients received 4 cycles and 5 patients received 6 cycles of CTX 
concomitant with RT.  










Side Effects and Tolerability 
Overall, CTX concomitant with RT was well tolerated by the patients. Skin reactions, known to be 
the most common side effect of CTX, were observed in all patients in various grades. During RT, 4 
patients had grade 2 and 5 patients had grade 3 toxicity according to the National Cancer Institute-
Common Terminology Criteria for Adverse Events (NCI-CTCAE) (table 1). An acneiform rash outside 
of the RT regions and frequently around the upper chest wall, upper back and gluteal region was 
observed following the second week of treatment. The grade of the rash based on the NCI-CTCAE was 
grade 1 in 5 patients and grade 2 in 4 patients (table 2). 
Xerosis cutis was seen in all patients in various grades. Paronychia-like reactions were observed in 2 
of 5 patients receiving 6 cycles of CTX. No electrolyte imbalance was seen in these cases.  
Statistical Analysis 
Five patients died 3, 5, 9, 10, and 18 months after completion of treatment, while the remaining 4 
patients are being followed up during the 3rd, 5th, and 12th month of treatment. Overall survival 
analysis of the patients was performed using the Kaplan-Meier method on SPSS version 15.0. Based on 
this calculation, mean follow-up duration is 12.8 months. Mean survival time is 19.8 months and the 
annual mean survival rate is 59.3%. 
Discussion 
Local-regional recurrence in SCHNC patients is still considered as the most important 
failure of treatment. More than 50% of the patients die because of local-regional 
recurrence. In recurrences and/or metastatic diseases, available treatment options are 
limited by the previously administered curative treatments. Rescue treatments are still 
popular and important as a standard of care. In the literature, there are no significant 
clinical trials including a high number of patients which prove the efficacy of second-line 
CT in SCHNC patients whose disease progresses following platinum-based CT. 
Accordingly, there is no commonly accepted treatment regimen available for this patient 
population [10]. While the first option for second-line CT almost always includes 
platinum-based agents, clinical efficacy of treatments including a combination of 
vinorelbine, docetaxel, paclitaxel and pemetrexed or third-generation cytotoxic agents 
such as irinotecan is also discussed [1]. A review of retrospective analyses shows that in 
patients with recurrent and/or metastatic disease who receive single-agent CT such as 
cisplatin, methotrexate, 5-fluorouracile (5-FU) and bleomycine, response rates are 
between 15 and 30%, with mean survival time being 3–5 months [11, 12]. Patients who 
cannot tolerate single-agent CT have difficulties in tolerating combination therapies with 
the addition of new agents as well. Mean survival time with combination CT is around 6–
9 months. Cisplatin/5-FU (PF) is the most widely used combination regimen in patients 
with recurrent and/or metastatic SCHNC. In a phase 3 study of 249 patients by Jacobs et 
al. [13], PF combination was compared with cisplatin alone and 5-FU alone, and response 
rates were observed as 32% in PF, 17% in cisplatin and 13% in 5-FU arms (p = 0.035), 
although overall survival was not significantly different between the 3 arms. In the 
intergroup E1395 study [14] of the Eastern Cooperative Oncology Group including 218 
patients, paclitaxel + cisplatin (PP) combination was compared with PF combination, and 
response rates of 27 and 26%, respectively, were found. Mean survival time was 8.1 
months in the PP arm and 8.7 months in the PF arm. The frequencies of grade 3–4 
toxicities were similar between both groups. Based on these results, PP combination can 
be considered as an alternative to PF combination. In the phase 2 study by Janinis et al.  










[15] comparing the combination of PF with docetaxel with PF combination, mean 
survival time in the docetaxel arm was 11 months, but febrile neutropenia was observed 
in 15% of the patients. In a phase 2 study by Benasso et al. [16] including 47 patients, 
mean survival time with paclitaxel + PF combination was 7.9 months, but grade 3–4 
neutropenia was seen in 48% of the patients. 
These results show that independent of which drugs are combined, combination 
treatment overall results in better survival compared to single-agent regimens with 
methotrexate, cisplatin or 5-FU. Combination CT should be preferred, especially in 
young and symptomatic patients with good performance status, to decrease the 
symptoms of disease [1]. EGFR is a member of the HER family and is a transmembrane 
receptor. Following binding of ligands, the receptor undergoes autophosphorylation and 
activates tyrosine kinases. Autophosphorylation results in activation of intracellular 
pathways that stimulate cancer proliferation, inhibition of apoptosis, activation of 
metastases and invasion, as well as tumor neovascularization. Abnormal levels of EGFR 
expression have been demonstrated in 80–100% of head and neck tumors. There is a 
positive correlation between the level of EGFR expression and bad prognosis, metastatic 
disease and low survival time. 
CTX is an IgG1 monoclonal antibody that binds to the extracellular chain of EGFR and 
maintains its activation, while preventing autophosphorylation and tyrosine kinase 
activation. Consequently, it blocks the rest of the pathway and the occurrence of 
consecutive events [17]. Synergy of CTX with the antitumor effects of cisplatin has been 
demonstrated in xenograft models [6]. The addition of CTX to CT in patients with 
recurrent and persistent SCHNC has been shown to cause significant increase in response 
rate without increasing toxicity. 
In a phase 2 study by Baselga et al. [8] comparing platinum-based CT + weekly CTX 
with platinum-based CT alone in 96 patients with platinum-resistant SCHNC, mean 
survival time in CT + CTX and CT alone arms was 183 days and 85 days, respectively. In 
a phase 3 study performed by Vermorken et al. [9] in patients with recurrent and/or 
metastatic head and neck cancer, the addition of CTX to standard dose cisplatin + 5-FU 
CT resulted in an increase of 2.7 months’ mean survival time and a 20% decrease in the 
risk of death. In a study by Bonner et al. [4] comparing the local-regional control upon 
concomitant use of CTX with RT to RT alone in patients with locally advanced SCHNC, 
the results were significantly in favor of the RT + CTX arm. Mean survival time was 49 
months in the RT + CTX arm, but 29.3 months in the RT alone arm. The effects of CRT 
and CTX + RT in patients with locally advanced head and neck cancer were compared in 
the RTOG study performed by Caudell et al. [18]. The 3-year local-regional control rate 
in the CTX + RT arm and the CRT arm was 70.7 and 74.7%, respectively, with the 
difference being statistically insignificant. The 3-year distant metastases-free survival rate 
was similar, 92.4% in the CTX + RT arm and 86.6% in the CRT arm. The 3-year disease-
free survival rate was 76.5% in the CRT arm and 78.6% in the CTX + RT arm, without any 
statistically significant difference between both groups. Although CTX + RT seems 
superior to today’s standard CRT regimens according to indirect comparisons performed 
between patients with locally advanced disease, there are still no phase 3 studies 
comparing these 2 regimens directly. In the ongoing phase 3 randomized RTOG 0522 
study, the efficacy of the addition of CTX to CRT in naive locally-advanced SCHNC 
patients is being investigated.  










Second-line radiation is a common rescue therapy in patients with recurrent and/or 
metastatic SCHNC. As in primary treatment, the administration of CT concomitant with 
RT in recurrent and/or metastatic disease increases local-regional control and survival 
time. Although concomitant treatment commonly involves platinum-based 
chemotherapeutic agents, treatment outcomes are not always satisfactory. The addition of 
taxanes to the treatment regimens of patients with good performance status leads to high 
toxicity despite the increase in 2-year survival rates, compared to a 5–45% increase seen 
with cisplatin concomitant with RT [10]. In their study including 38 patients with 
recurrent unresectable SCHNC, Kramer et al. [19] administered cisplatin and paclitaxel 
concomitant with split-course radiation and reported a 2-year survival rate of 35% and a 
1-year disease-free survival rate of 33%. Treatment-associated morbidity rates were 
acceptable. Five-year local-regional control and overall survival in 29 patients with 
recurrent or second primary SCHNC who underwent hyperfractionated regimens 
concomitant with gemcitabine, paclitaxel and 5-FU were 26 and 45%, respectively; 
however, the ratio of late toxicities secondary to RT was relatively high [20]. Although it is 
difficult to derive any conclusions from small patient populations, better tumor control 
and higher survival rates have been reported with regimens including CT involving 
taxanes concomitant with second-line radiation; these advantages are, however, 
accompanied by significantly increased rates of acute and late morbidities. There are no 
studies in the literature demonstrating that the efficacy of CTX concomitant with RT 
observed in locally advanced disease also applies to recurrent and/or metastatic disease. 
We administered CTX concomitant with second-line RT to 9 patients in our clinics, 
including 2 with carcinoma of the larynx with recurrence in tracheostomy, 2 with 
carcinoma of the larynx with neck metastasis, 2 with carcinoma of the lip with neck 
metastasis, 2 with carcinoma of the mouth base with recurrence, and 1 patient with 
carcinoma of the tongue base with neck metastasis. All of these patients had previously 
received curative treatments for primary disease. Second-line RT of these patients, who 
had SCHNC (except nasopharynx) and whose disease was considered inoperable and 
progressed under platinum-based or taxane regimens, including CT, or in whom these 
treatments were contraindicated, was planned conformally in 3-D considering tolerance 
doses of critical organs such as the spinal cord or mandibula. Four of 5 patients with neck 
metastases received 20 Gy, 1 received 30 Gy, 1 of 2 patients with carcinoma of the mouth 
base received 40 Gy, 1 received 20 Gy and 2 patients with recurrence in tracheostomy 
received 70 Gy of RT. All patients received CTX concomitant with RT. Both treatments 
were well tolerated by the patients. Four patients had grade 2 and 5 patients had grade 3 
radiation dermatitis according to NCI-CTCAE toxicity evaluation criteria (fig. 1). 
According to a review of the side effects of CTX by Galimont-Collen et al. [21], the most 
frequent adverse event reported in patients undergoing CTX treatment was grade 1 (50%) 
followed by grade 2 (14%) acne-like rash. Grade 3 and 4 toxicities are very rare. In parallel 
with these data, 5 patients in the present cohort had grade 1 and 4 had grade 2 acne-like 
rash (fig. 2 and fig. 3). Consistent with previous reports in the literature, common areas 
outside of the RT region where acne-like rash was observed included the upper back, 
upper chest wall and gluteal region. Xerosis cutis was observed in all patients in various 
grades. Painful paronychia-like reactions of the nails were observed in 2 of 5 patients 
receiving 6 cycles of CTX. Rarely observed hairy skin lesions and telangiectasia that are 
associated with the effects of EGFR inhibitors on capillary vessels were not seen in the 
present cohort. Concomitant CTX did not increase RT-associated toxicity in any of the 
patients.  










Mean post-treatment follow-up duration was 12.8 months. Mean survival was 19.8 
months with a mean annual survival rate of 59.3%. Vermoken et al. [22] performed a 
meta-analysis of studies including single-agent CTX or CTX combined with CT, and 
reported a mean survival of 5.9 months with CTX alone and 5.2–6.1 months with 
combination regimens. Although the present study included a relatively low number of 
patients, the mean survival time was evidently longer. However, we cannot make a clear 
comparison as there is no reference study in the literature to compare the present figures 
with. Recently, Balermpas et al. [23] performed a study in 7 patients with inoperable 
recurrence of SCHNC; second-line RT with concomitant CTX was administered but only 
toxicity assessment was done. 
In the ongoing phase 2 NCT00226239 study, patients with stage 3–4 SCHNC are being 
randomized to CTX + RT or CT + RT arms following neoadjuvant TPF treatment. RTOG 
0522 and RTOG 0234 studies are also ongoing CTX studies. RTOG 0522 is a phase 3 
study designed to randomize naive patients with locally advanced SCHNC to  
CT + RT and CT + RT + CTX arms. The results of these studies will clarify the 
importance of CTX in SCHNC treatment. Although CTX is approved for use in first-line 
treatment of recurrent and/or metastatic SCHNC in the USA and most European 
countries, it is approved for use in Turkey as a radiosensitizer concomitant with RT only 
in patients with locally advanced head and neck cancer in whom CT is contraindicated, 
except for carcinoma of the nasopharynx. 
Conclusion 
In our opinion, although CTX might appear to be an expensive treatment option, the 
addition of CTX to the treatment regimen will significantly reduce overall treatment costs 
since the sensitivity of disease to both CT and RT increases in patients with recurrent 




Table 1. Toxicity grading of radiation dermatitis according to the NCI-CTCAE 




  Moderate to brisk 
erythema; patchy moist 
desquamation, mostly 
confined to skin folds 
and creases; moderate 
edema 
  Moist desquamation in 
areas other than skin 
folds and creases; 
bleeding induced by 
minor trauma or 
abrasion 
  Skin necrosis or 
ulceration of full 
thickness dermis; 
spontaneous bleeding 














Table 2. Toxicity grading of acne-like rash according to the NCI-CTCAE 
Grade 1    Grade 2    Grade 3    Grade 4 
Macular or papular 
eruption or erythema 
without associated 
symptoms 
  Localized follicular fistula 
on <50% of body surface 
area and pruritus 
  Localized follicular fistula 
on >50% of body surface 
area and pruritus 










Fig. 2. Grade 1 acne-like rash. 
 
  











Fig. 3. Grade 2 acne-like rash. 
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